Gadolinium-based contrast agents (GBCAs) are extensively used in magnetic resonance imaging (MRI) to improve the visibility of blood vessels, tumors, inflammation, along with other internal buildings. Even though commonly viewed as Harmless, issues about GBCA toxicity have emerged in the last 20 years—particularly in clients with impaired kidney